Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
NCT00775073
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
INDIV
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Everolimus, Bevacizumab
Sponsor
Gerhard Treiber
Collaborators
[object Object]
[object Object]
[object Object]